|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM111487986 |
| 003 |
DE-627 |
| 005 |
20240704231810.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n1460.xml
|
| 035 |
|
|
|a (DE-627)NLM111487986
|
| 035 |
|
|
|a (NLM)11237557
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Reilly, C M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prostaglandin J(2) inhibition of mesangial cell iNOS expression
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.03.2001
|
| 500 |
|
|
|a Date Revised 04.07.2024
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a Mesangial cells from MRL/lpr mice, a model of lupus, overproduce nitric oxide (NO) compared to controls. J series prostaglandins (PG) and thiazolidinediones block LPS stimulation of NO production via the activation of peroxisome proliferator-activator receptor-gamma (PPAR-gamma) in macrophages but utilize an alternative mechanism in microglial cells. We investigated the mechanism by which PGJ(2) inhibits NO production in LPS/IFN-gamma-stimulated MRL/lpr mesangial cells. Our results demonstrated that LPS/IFN-gamma addition to MRL/lpr mesangial cells stimulated iNOS activation, expression of p-38 kinase and p44/42 MAPK, and NF-kappaB translocation to the nucleus. Both pioglitazone, a specific PPAR-gamma agonist, and PGJ(2) blocked NO production, iNOS protein expression, and iNOS mRNA transcription. PGJ(2) failed to inhibit nuclear NF-kappaB translocation or p44/42 MAPK or p-38 kinase induction in stimulated mesangial cells. These data suggest that PGJ(2) blocks iNOS expression and subsequent NO production in mesangial cells via a PPAR-gamma-mediated mechanism either by interfering with NF-kappaB transcriptional activity or by an NF-kappaB-independent mechanism
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Lipopolysaccharides
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Cytoplasmic and Nuclear
|2 NLM
|
| 650 |
|
7 |
|a Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a 9-deoxy-delta-9-prostaglandin D2
|2 NLM
|
| 650 |
|
7 |
|a 60203-57-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide Synthase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide Synthase Type II
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 650 |
|
7 |
|a Nos2 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 650 |
|
7 |
|a Mitogen-Activated Protein Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.24
|2 NLM
|
| 650 |
|
7 |
|a Prostaglandin D2
|2 NLM
|
| 650 |
|
7 |
|a RXY07S6CZ2
|2 NLM
|
| 700 |
1 |
|
|a Oates, J C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sudian, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Crosby, M B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Halushka, P V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gilkeson, G S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 98(2001), 3 vom: März, Seite 337-45
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:98
|g year:2001
|g number:3
|g month:03
|g pages:337-45
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 98
|j 2001
|e 3
|c 03
|h 337-45
|